Drug Search Results

Omarigliptin

Alternative Names: omarigliptin, mk-3102
Latest Update: 2024-06-11
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: DPP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Omarigliptin

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Type 2 Diabetes

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
2012-002414-39	P3	Completed	Type 2 Diabetes	2023-02-13

Recent News Events

Date	Type	Title
02/01/2024	PubMed	Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
09/01/2023	PubMed	Omarigliptin inhibits brain cell ferroptosis after intracerebral hemorrhage.
08/03/2023	PubMed	Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions